Targets › THRB
11 programs from 11 companies in 21 trials: 8 Phase 2, 6 Phase 3, 5 Phase 4, 2 Phase 1; Metabolic and endocrine, Gastroenterology, Other; next expected readout Nov 2026.
Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine. (UniProt, P10828)
Open in Phaseline: the race on THRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Elyes Kamoun | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 4 | Hypothyroidism Primary | Dec 2026 |
| Madrigal Pharmaceuticals | Resmetirom Thyroid hormone receptor beta-1 agonist | THRB | Phase 4 | MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH; Non-Alcoholic Fatty Liver Disease; NASH - Nonalcoholic Steatohepatitis … | Dec 2026 |
| University of Pennsylvania | Levothyroxine Sodium Thyroid hormone receptor agonist | THRA, THRB | Phase 4 | Hypothyroidism | Apr 2028 |
| Daihong Liu | Anti-Thymocyte Globulin (ATG) (Thymoglobulin) Anti-thymocyte immunoglobulin; depletes T cells through immune recognition | THRA, THRB | Phase 4 | Hematopoietic Stem Cell Transplantation | Aug 2028 |
| Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 3 | Obesity | Nov 2026 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 3 | Hypothyroidism; Irradiation | Sep 2029 |
| Rare Thyroid Therapeutics International | Tiratricol Thyroid hormone receptor agonist | THRA, THRB | Phase 2 | Allan-Herndon-Dudley Syndrome | Jul 2027 |
| AbbVie | Armour Thyroid Thyroid hormone replacement containing levothyroxine (T4) and liothyronine (T3) | THRA, THRB | Phase 2 | Hypothyroidism | Sep 2027 |
| UConn Health | Levothyroxine Thyroid hormone receptor agonist | THRA, THRB | Phase 2 | Hypothyroidism | Dec 2027 |
| VA Office of Research and Development | Levothyroxine Sodium Thyroid hormone receptor agonist | THRA, THRB | Phase 2 | Nonalcoholic Steatohepatitis | Dec 2029 |
| Sabine Mueller, MD, PhD | Liothyronine (L-T3) Thyroid hormone T3 receptor agonist for immunotherapy | THRB | Phase 1 | Medulloblastoma | Mar 2031 |
Hypothyroidism (4) Hematopoietic Stem Cell Transplantation (3) MASH - Metabolic Dysfunction-Associated Steatohepatitis (3) Hypothyroidism; Irradiation (1) NASH (1) Non-Alcoholic Fatty Liver Disease (1) NASH - Nonalcoholic Steatohepatitis (1) MASH (1) MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease (1) Hypothyroidism Primary (1) Obesity (1) Allan-Herndon-Dudley Syndrome (1)
small molecule (9), protein or peptide (1), mixed (1)
Daihong Liu (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) Madrigal Pharmaceuticals (1) Elyes Kamoun (1) Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) Rare Thyroid Therapeutics International (1) AbbVie (1) University of Pennsylvania (1) Sabine Mueller, MD, PhD (1) UConn Health (1) VA Office of Research and Development (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.